The Consortium

THE CONSORTIUM

The Tau Consortium is an international group of clinical and basic scientists who work together with a sense of urgency to understand, treat, and cure tau-related disorders (tauopathies) including progressive supranuclear palsy, frontotemporal dementia with parkinsonism and corticobasal degeneration. The consortium studies tau in a comprehensive manner with the goal of understanding how changes in the gene and protein lead to neurodegenerative disease. Within the Tau Consortium, research findings are formally shared with the goal of stimulating new ideas and generating new partnerships across our distributed laboratories. The primary goal of this consortium is to speed the discovery of treatments for diseases caused by the abnormal accumulation of tau.

The Tau Consortium was founded in 2010 to find a cure for diseases related to the protein tau. The Rainwater Charitable Foundation brought together a group of physicians and scientists to work in a precision medicine space to advance research into progressive supranuclear palsy, chronic traumatic encephalopathy, and related disorders that have tau aggregation as the underlying mechanism. The Foundation created an environment where highly collaborative experts could come together and share research methods, ideas and results in a protected space. The Consortium currently provides funding and infrastructure for 30 different investigators from around the United States and Europe to work on highly specific research projects designed to better diagnose and treat tau-related disorders.

The Tau Consortium has already had a significant impact. Within the first year of existence, the Consortium evaluated compounds that were FDA approved for safety and tolerability in other conditions. This effort has led to the identification of a broad variety of potential therapies. Recently, the Consortium launched meetings to begin the planning of clinical trials with investigators around the world sharing research study design, patients, and data. While the number of people with disease involving tau exclusively may be small, the ultimately successful approach will likely apply to Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Lewy body dementia, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), and other diseases that involve misfolded proteins.